輝煌科技(08159.HK):聯席主席王漓峯被調任為董事會副主席
格隆匯3月4日丨輝煌科技(08159.HK)宣佈,由於工作調動關係,執行董事兼董事會聯席主席王漓峯已被調任為董事會副主席,自2022年3月4日起生效。王漓峯於調任為董事會副主席後,仍然為執行董事、公司執行委員會主席、公司策略及發展委員會主席及公司薪酬委員會成員。
同日宣佈,倪弦已被委任為執行董事,自2022年3月4日起生效。同時,許琳已被委任為獨立非執行董事,自2022年3月4日起生效。
董事會宣佈,馮申為投放更多時間於彼之其他業務,彼已於根據委任書上任期在2022年3月4日屆滿後,分別退任獨立非執行董事、公司審核委員會、薪酬委員會、公司提名委員會、執行委員會及策略及發展委員會成員。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.